Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome

• Status: Completed
• Trial end date: 2020-09-06
• Target enrollment: 0
• Participant gender: All

Summary

The burning mouth syndrome (BMS) is a chronic pain syndrome of the oral mucosa. Feels like experiencing a burning sensation, pain, stinging, or numbness in the mouth along with a feeling of dryness, paraesthesia, taste disturbance or hypersensitivity.The complaints are usually bilateral, of moderate intensity, they persist for a minimum of 4-6 months and concern the clinically unchanged membrane mucous.The psychiatric aspect of BMS is very important. The presence of BMS has been shown to be associated with depression, increased anxiety levels, hypochondria, and carcinophobia and emotional instability

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wroclaw Medical University
• Treatments: Clonazepam

Criteria

Inclusion Criteria:

• History of BMS for at least 6 months

• no clinical changes in the oral cavity that are clinically verifiable and may affect symptoms,

• no previous BMS therapy

• age over 18

Exclusion Criteria:

• V and VII nerve neuralgia

• patients with uncontrolled diabetes mellitus,

• thyroid disease, anemia,

• Sjogren's disease and

• connective tissue disease (fibromyalgia),

• patients after prior surgical / neurosurgical treatment of the head,

• oncological treatment (radiotherapy),

• pregnant women,

• the occurrence of clinical pathologies in the oral cavity that may cause pain,

• deficiencies of vitamin B12, folic acid